Research ArticleOriginal Research
Trimethoprim-Sulfamethoxazole or Clindamycin for Community-Associated MRSA (CA-MRSA) Skin Infections
Christopher R. Frei, Monica L. Miller, James S. Lewis, Kenneth A. Lawson, Jonathan M. Hunter, Christine U. Oramasionwu and Robert L. Talbert
The Journal of the American Board of Family
Medicine November 2010, 23 (6) 714-719; DOI: https://doi.org/10.3122/jabfm.2010.06.090270
Christopher R. Frei
PharmD, MSc, BCPS
Monica L. Miller
PharmD, MSc
James S. Lewis II
PharmD
Kenneth A. Lawson
PhD
Jonathan M. Hunter
MA
Christine U. Oramasionwu
PharmD, MSc, BCPS
Robert L. Talbert
PharmD, BCPS

References
- ↵
- ↵Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41: 1373–406.
- ↵Ellis MW, Lewis JS 2nd. Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr Opin Infect Dis 2005; 18: 496–501.
- ↵Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA, Participants in the Centers for Disease Control and Prevention-Convened Experts’ Meeting on Management of MRSA in the Community. Strategies for clinical management of MRSA in the community: summary of an experts’ meeting convened by the Centers for Disease Control and Prevention. March 2006. Available at: http://www.cdc.gov/ncidod/dhqp/pdf/ar/CAMRSA_ExpMtgStrategies.pdf. Accessed 31 July 2009.
- ↵Parchman ML, Munoz A. Risk factors for methicillin-resistant Staphylococcal aureus skin and soft tissue infections presenting in primary care: a South Texas Ambulatory Research Network (STARNet) study. J Am Board Fam Med 2009; 22: 375–9.
- ↵Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007; 51: 423–8.
- ↵Elwell LP, Wilson HR, Knick VB, Keith BR. In vitro and in vivo efficacy of the combination trimethoprim-sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1986; 29: 1092–4.
- ↵Close SJ, McBurney CR, Garvin CG, Chen DC, Martin SJ. Trimethoprim-sulfamethoxazole activity and pharmacodynamics against glycopeptide-intermediate Staphylococcus aureus. Pharmacotherapy 2002; 22: 983–9.
- ↵Cenizal MJ, Skiest D, Luber S, et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 2628–30.
- ↵
- ↵Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007; 51: 4044–8.
- ↵Centers for Disease Control and Prevention. MRSA infections. Available at: http://www.cdc.gov/mrsa/index.html. Accessed 24 September 2010.
In this issue
The Journal of the American Board of Family
Medicine
Vol. 23, Issue 6
November-December 2010
Trimethoprim-Sulfamethoxazole or Clindamycin for Community-Associated MRSA (CA-MRSA) Skin Infections
Christopher R. Frei, Monica L. Miller, James S. Lewis, Kenneth A. Lawson, Jonathan M. Hunter, Christine U. Oramasionwu, Robert L. Talbert
The Journal of the American Board of Family
Medicine Nov 2010, 23 (6) 714-719; DOI: 10.3122/jabfm.2010.06.090270
Trimethoprim-Sulfamethoxazole or Clindamycin for Community-Associated MRSA (CA-MRSA) Skin Infections
Christopher R. Frei, Monica L. Miller, James S. Lewis, Kenneth A. Lawson, Jonathan M. Hunter, Christine U. Oramasionwu, Robert L. Talbert
The Journal of the American Board of Family
Medicine Nov 2010, 23 (6) 714-719; DOI: 10.3122/jabfm.2010.06.090270
Jump to section
Related Articles
- No related articles found.
Cited By...
- Chiral evasion and stereospecific antifolate resistance in Staphylococcus aureus
- Multidrug and Mupirocin Resistance in Environmental Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates from Homes of People Diagnosed with Community-Onset MRSA Infection
- Antibacterial Antifolates: From Development through Resistance to the Next Generation
- Treatment Failure and Costs in Patients With Methicillin-Resistant Staphylococcus aureus (MRSA) Skin and Soft Tissue Infections: A South Texas Ambulatory Research Network (STARNet) Study
- Dose of Trimethoprim-Sulfamethoxazole To Treat Skin and Skin Structure Infections Caused by Methicillin-Resistant Staphylococcus aureus
- Prevalence, Severity, and Treatment of Community-Acquired Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Skin and Soft Tissue Infections in 10 Medical Clinics in Texas: A South Texas Ambulatory Research Network (STARNet) Study
- Response: Re: Trimethoprim-sulfamethoxazole or Clindamycin for Community-Associated MRSA (CA-MRSA) Skin Infections
- Re: Trimethoprim-sulfamethoxazole or Clindamycin for Community-Associated MRSA (CA-MRSA) Skin Infections
- This Issue: International Issues, Infectious Diseases, Medical Liability, and Medical Home Ideas